Hormonal and metabolic characteristic of androgen deficiency and its correction by testosterone in men with type 1 diabetes mellitusundergoing programmed hemodialysis

Aim.
To study the prevalence of androgen deficiency in men with type 1 diabetes mellitus (DM1) undergoing programmed hemodialysis (PHD) andto develop methods for the treatment of metabolic disorders.
Materials and methods.
The study included 43 men with DM1 on PHD. Group 1 comprised 20 patients below 40 years of age, group 2 included23 older patients. Patients of group 1 were allocated to subgroup A (treated with testosterone and ether mixture (TEM)); and control subgroup B(n=14 and 6 respectively). Patients of group 2 were divided into subgroup C (treated with TEM) and control subgroup D (n=14 and 9 respectively).Patients in the study and control subgroups were matched for age, duration of DM1, hemodialysis (years), total testosterone (TT, nmol/l), hemoglobin(Hb, g/l) and glycated hemoglobin (HbA_1c, %) levels. All the patients were treated with epoetin-beta (EPO-b) on an individual basis depending onHb level; TEM was given thrice weekly.
Results.
Group 1: age 34.0?3.9 yr, HbA_1c 9.3?1.4%, Hb 118.1?9.6 g/l, TT 21.2?6.6 nmol/l. Group 1: age 47.3?3.5 yr, HbA_1c 9.5?1.8%,Hb 94.9?5.7 g/l, TT 9.8?3.9 nmol/l. Androgen deficiency was diagnosed in 48.8% (total group), 5.0% (group 1) and 86.9% (group 2) of the patients.Reduction of TT level was not accompanied by a significant rise in LH concentration to above normal values (p>0.05). HbA_1c level in eithergroup did not significantly change within 6 months after the onset of the study. Combined treatment with EPO-b and TEM resulted in a Hb concentrationof 118.2?6.7 g/l in subgroup A (p=0.79). Hb level in subgroup C increased to 113.5?6.3 g/l (p=0.009). Hb changes in control groups wereinsignificant. Requirement for EPO-b in subgroups A and C decreased by 32.1% (p=0.007) and 41.1% (p=0.001) respectively but remained unalteredin both control subgroups.
Conclusion.
Reduction of the TT level in men with DM1 on PHD is a function of age and constitutes an independent risk factor of anemia. Androgendeficiency and its correction have no effect on carbohydrate metabolism. Combined treatment with EPO-b and TEM increases blood Hb level in oldermen and reduces requirement for EPO-b regardless of the age.

diabetes mellitus, androgen deficiency, hemodialysis

1. U.S. Renal Data System: Annual Data Report. Atlas of End Stage Renal Disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases. - 2003.

2. Бикбов Б.Т., Томилина Н.А. О состоянии заместительной терапии больных с хронической почечной недостаточностью в Российской Фе- дерации в 1998 - 2005 гг. // Нефрология и диализ. - 2007. - Т. 7, №1. - С. 6-8

3. Гончаров Н.П., Кация Г.В., Калинченко С.Ю., Тодуа Т.Н., Ма лышева Н.М. Метаболизм андрогенов у мужчин, больных сахарным диабетом 1 типа //Проблемы эндокринологии. - 2001. - Т. 47, №4. С. 23-26.

4. Ермоленко В.М., Иващенко М.А. Уремия и эритропоэтин. Методиче- ское пособие. - 2000. - 104 с.

5. Лопаткин Н.А. Руководство по урологии. - М., 1998. - 672 с.

6. Abero К., Jangula J., Jain S. et al. Aluminium uptake end toxicity in cultured mouse hepatocytes // J. Am. Soc. Nephrol. - 1990. - Vol. 11. - P. 1229-1304.

7. Bhasin S., et al: Effects of an oral androgen on muscle and metabolism in older, community-dwelling men // Am. J. Physiol. Endocrinol. Metab. - 2003. - 284. - Vol. 284, Issue 1. - P. E120-E128.

8. Gascуn A., Belvis J.J., Berisa F., et al. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis // Ger. Nephrol. Urol. -1999. - 9. - P. 67-72.

9. Navarro J.F., Mora C. Effect of androgens on anemia and malnutrition in renal failure: implications for patients on peritoneal dialysis // Perit. Dial. Int. - 2001. - 21. - P. 14-24.

10. Гончаров Н.П., Кация Г.В., Калинченко С.Ю., Тодуа Т.Н. и др. Современ- ные подходы к оценке андрогенной функции у мужчин на модели сахар- ного диабета 1 и 2 типа: значение биологически доступного, свободного и общего тестостерона // Андрология и генитальная хирургия. - 2003. - №2. - C. 53-57.

11. Everaerd W. Chronic renal failure and sexual functioning: clinical status versus objectively assessed sexual response // Nephrology Dialysis Transplantation. - 1997. - 12. - P. 2645-2663.

12. Horl W.H. Non-erythropoietin-based anaemia management in chronic kidney disease // Nephrol. Dial. Transplant. - 2002. - 17 Suppl. 11. - P. 35-38.

13. Morales A., Lunenfeld B. Investigation, treatment and monitoring of lateonset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male // Aging Male. - 2002. - 5. - P. 74-86.

14. Navarro J.F., Mora C. Androgen therapy for anemia in elderly uremic patients // Int. Urol. Nephrol. - 2001. - 32. - Р. 549-557.

15. Teruel J.L., Marcйn R., Navarro J. et al. Androgen versus erythropoietin for the treatment of anemia in hemodialysis patients: a prospective study // J. Am. Soc. Nephrol. - 1996. - 7. - Р. 140-144.

16. Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging // J. Clin. Endocrinol. Metab. - 2001. - Feb.; 86(2). - Р. 724-731.

17. Рациональная фармакотерапия заболеваний эндокринной системы и нарушений обмена веществ: Руководство по эндокринологии, Т. XII /Под ред. И.И. Дедова, Г.А. Мельниченко. - Москва. - 2006. - 584 c.

18. Handelsman D.J., Dong Q. 1993 Hypothalamo-pituitary gonadal axis in chronic renal failure //Endocrinol. Metab. North. Am. 22. - Р. 145- 159.

19. Шестакова М.В., Лепетухин А.Е., Кварацхелия М.В. Рожинская Л.Я., Андрусев А.М., Кирхман В.В. Ведение больных сахарным диабетом с терминальной хронической почечной недостаточностью на диализе: Методические указания /Под ред. И.И. Дедова, Н.А.Томили- ной. - М., 2004. - 62 с.